Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.
RCT-duplicate (RCT-D) is an initiative led by the Brigham and Women's Hospital and Harvard Medical School, that selected 30 clinical trials as part of an empirical experiment where these trials would be emulated using RWD. AstraZeneca will replicate three emulations CANVAS, LEADER, and SAVOR TIMI from among the 30 plus clinical trials analyzed in RCT-D. These clinical trials assess type 2 diabetes mellitus drugs. The replications will be conducted on the Instant Health Data PANALGOS (IHD) platform to assess these studies in two claims databases Optum and IBM Watson Market Scan. The aim is to recreate these three emulations to investigate the reproducibility of the emulations, increase transparency and better understand the process of trial emulations; and where possible, contribute with potential improvements to the RCT-D framework.
Study Type
OBSERVATIONAL
Enrollment
239,990
Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
Research Site
Gothenburg, Sweden
3-point MACE
3-point MACE: Relative hazard of composite outcome of Stroke, MI, and Mortality
Time frame: Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication